Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact

John Carroll

Editor & Founder

Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact